0
Moderna’s COVID-19 vaccine demonstrates 94.5% efficacy
Just 1 week after Pfizer and BioNTech’s early Phase III trial data were released, more good news comes from Moderna’s…
Browsing: Basic > Drug Development
0
The importance of bacteriophage collections – an interview with Juandem Agendia and Sarah Alexander
In this podcast, Juandem Agendia and Sarah Alexander (NCTC, UK) discuss bacteriophages, the function of the NCTC and the importance…
0
Infographic: Tackling antimicrobial resistance with phages
Phages are a promising alternative to antibiotics, especially considering the looming increase in multidrug-resistant bacteria. This infographic further explores what…
0
Accelerate your COVID-19 bioanalytical research while saving time and reducing cost
Wednesday 18 November 2020 11:00 [EST] 08:00 [PST] 16:00 [GMT] Alternative time zones REGISTER NOW The pharmaceutical industry is in…
0
Coronavirus research tools: Cayman Chemical
Identifying drugs and developing rapid and accurate diagnostic tests for SARS-CoV-2 are currently at the forefront of the infectious disease…
0
Application of bacteriophages to overcome antimicrobial resistance
Bacteriophages (viruses that invade bacteria and can kill them) have gained renewed interest as part of measures to combat the…
0
COVID-19: success seen in Synairgen inhalable drug trial
In collaboration with the University of Southampton, Synairgen (both Southampton, UK) have announced positive results from their recent trial of SNG001, a novel protein based COVID-19 drug.
0
Four new compounds identified for COVID-19 drug repurposing
In a collaborative study between the University of South Florida (USF Health; FL, USA) and the University of Arizona College of Pharmacy (AZ, USA), several existing drugs have been identified as potential therapies for COVID-19.
0
Antiviral strategies for emerging infectious diseases: Cayman Chemical
The emergence and global spread of SARS-CoV-2 has prompted scientific study on an unprecedented scale, with an urgent need for…
0
Confronting COVID-19 head on at the Wyss Institute
Harvard’s Wyss Institute is leveraging its unique technology innovation capabilities to develop diagnostic, therapeutic, and vaccine interventions for COVID-19 at lightning speed.